Overview

VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate

Status:
Terminated
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Vesicare (Solifenacin succinate) is effective in treating over-active bladder symptoms during radiation therapy of the prostate.
Phase:
Phase 4
Details
Lead Sponsor:
Advanced Research Network
Collaborator:
Astellas Pharma US, Inc.
Treatments:
Solifenacin Succinate